Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-8-3
pubmed:abstractText
Previous exposure to a nonlethal ischemic insult protects the brain against subsequent harmful ischemia. N-methyl-D-aspartate (NMDA) receptors are a highly studied target of neuroprotection after ischemia. Recently, NMDA receptor subtypes were implicated in neuronal survival and death. We focused on the contribution of NR2A and cyclic-AMP response element (CRE)-binding protein (CREB) signaling to ischemic tolerance using primary cortical neurons. Ischemia in vitro was modeled by oxygen-glucose deprivation (OGD). Ischemic tolerance was induced by applying 45-mins OGD 24 h before 180-mins OGD. Sublethal OGD also induced cross-tolerance against lethal glutamate and hydrogen peroxide. After sublethal OGD, expression of phosphorylated CREB and CRE transcriptional activity were significantly increased. When CRE activity was inhibited by CREB-S133A, a mutant CREB, ischemic tolerance was abolished. Inhibiting NR2A using NVP-AAM077 attenuated preconditioning-induced neuroprotection and correlated with decreased CRE activity levels. Activating NR2A using bicuculline and 4-aminopiridine induced resistance to lethal ischemia accompanied by elevated CRE activity levels, and this effect was abolished by NVP-AAM077. Elevated brain-derived neurotrophic factor (BDNF) transcriptional activities were observed after sublethal OGD and administration of bicuculline and 4-aminopiridine. NR2A-containing NMDA receptors and CREB signaling have important functions in the induction of ischemic tolerance. This may provide potential novel therapeutic strategies to treat ischemic stroke.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-10024352, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-10600750, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-11425894, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-11691980, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-11717354, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-11893339, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-11909726, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-11919510, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-11953750, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-12194863, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-12439285, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-12849400, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-14568745, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-14743453, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-15234351, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-15356193, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-15369669, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-15580338, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-15647742, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-16641230, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17018022, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17073817, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17088105, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17213861, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17234586, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17261713, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17261715, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-17360906, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-18516035, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-18688011, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-18711223, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-19296922, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-19734892, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-1997501, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-2245337, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-7512349, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-8461137, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-9016349, http://linkedlifedata.com/resource/pubmed/commentcorrection/20145658-9581764
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1559-7016
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1441-9
pubmed:dateRevised
2011-8-3
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Activation of NR2A receptors induces ischemic tolerance through CREB signaling.
pubmed:affiliation
Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan. yterasak@medone.med.osaka-u.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't